Saturday 17 October 2026
Export AKTS’s income statement to Excel — free account
Aktis Oncology, Inc.
AKTS Healthcare Biotechnology
Aktis Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.5 million, up 336.9% from fiscal 2024. Insiders bought in the last twelve months.
15.06
0.95
−5.93%
Follow AKTS
| Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 |
P/S ratio |
— | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | 6.87 | 3.64 |
P/FCF ratio |
— | 0.00 | 0.00 |
P/Operating CF |
— | (0.28) | (0.28) |
P/B ratio |
— | 0.00 | 0.00 |
Price to Tangible BV |
— | 0.00 | 0.00 |
EV/Sales |
— | 0.00 | 0.00 |
EV/EBITDA |
— | 0.00 | 0.00 |
EV/Operating CF |
— | 2.51 | 2.51 |
EV/FCF |
— | 2.11 | 2.11 |
Quick Ratio |
15.69 | 15.79 | 7.26 |
Current Ratio |
16.07 | 15.98 | 7.37 |
Net Debt/EBITDA |
2.66 | 5.45 | 2.95 |
Debt/Assets |
0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.01 | 0.02 |
Operating CF/Net income |
1.05 | (0.34) | 1.01 |
Capex/Depreciation |
1.83 | 1.14 | 4.18 |
| 0.00% | 65.59% | 54.48% | |
| 0.00% | (19.61%) | (21.56%) | |
ROIC |
(369.71%) | 0.00% | 0.00% |
Return on Tangible Assets |
(28.79%) | (15.20%) | (29.83%) |
Average Days of Receivables |
— | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 2,754.14% | 1,038.19% |
Selling, General and Administrative Expense of Revenue |
0.00% | 846.20% | 211.33% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 151.98% | 78.97% |
Graham Net Nets |
— | 8.44 | 8.44 |
Graham Number |
— | 0.00 | 0.00 |
Earnings Yield |
— | (129.71%) | (129.71%) |
Free Cash Flow Yield |
— | (546.91%) | (546.91%) |
Revenue per Share |
0.00 | 2.11 | 7.99 |
Operating CF per Share |
(48.77) | 20.96 | (78.83) |
Capex per Share |
(6.03) | (4.06) | (11.78) |
Free Cash Flow per Share |
(54.80) | 16.90 | (90.61) |
Cash per Share |
159.07 | 421.99 | 278.78 |
Shareholders Equity per Share |
168.63 | 348.77 | 230.19 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
168.63 | 348.77 | 230.19 |
Free Cash Flow |
(33.71) | 11.90 | (73.71) |
Working Capital |
93.97 | 282.03 | 199.07 |
Capital Expenditures |
(3.71) | (2.86) | (9.58) |
Net Current Asset Value |
81.59 | 220.28 | 152.69 |
EV/EBIT |
— | 0.00 | 0.00 |
Capex to Sales |
0.00 | 1.92 | 1.48 |
Price to Operating Income |
— | 0.00 | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
(0.37) | (0.34) | (0.16) |
Cash ROIC |
(16.72%) | 2.19% | (17.80%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 |
Average Payables |
— | 1.44 | 1.83 |
Average Assets |
— | 224.27 | 295.53 |
Average Common Equity |
— | (67.05) | (116.98) |
Columns are period end dates